Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

The Lancet

Volumn 385, Issue 9984, 2015, Pages 2272-2279

  Zhu, Feng Cai ^a   Hou, Li Hua ^b   Li, Jing Xin ^a   Wu, Shi Po ^b   Liu, Pei ^e   Zhang, Gui Rong ^c   Hu, Yue Mei ^a   Meng, Fan Yue ^a   Xu, Jun Jie ^b   Tang, Rong ^a   Zhang, Jin Long ^b   Wang, Wen Juan ^a   Duan, Lei ^d   Chu, Kai ^a   Liang, Qi ^a   Hu, Jia Lei ^a   Luo, Li ^e   Zhu, Tao ^d   Wang, Jun Zhi ^f   Chen, Wei ^b  

^a JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^c Institute for Drug and Instrument Quality Control of Health   (China)

^d Tianjin CanSino Biotechnology Inc   (China)

^e SOUTHEAST UNIVERSITY   (China)

^f NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; EBOLA VACCINE; GLYCOPROTEIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ADENOVIRUS TYPE 5 VECTOR BASED EBOLA VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHINA; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; LEUKOCYTE COUNT; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; T LYMPHOCYTE; VACCINATION; VOMITING; ADOLESCENT; EBOLAVIRUS; IMMUNOGENETICS; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PILOT STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; CLINICAL TRIALS, PHASE I AS TOPIC; EBOLA VACCINES; EBOLAVIRUS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGENETIC PHENOMENA; MALE; MIDDLE AGED; PILOT PROJECTS; YOUNG ADULT;

EID: 84934286956     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60553-0     Document Type: Article

References (27)

1. WHO Ebola Response Team Ebola virus disease in West Africa - the first 9 months of the epidemic and forward projections N Engl J Med 371 2014 1481 1495
2. WHO What this - the largest Ebola outbreak in history - tells the world http://www.who.int/csr/disease/ebola/ebola-6-months/lessons/en/ 2014 (accessed Dec 28, 2014).
3. JE Ledgerwood, AD DeZure, DA Stanley et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report N Engl J Med 2014 10.1056/NEJMoa1410863 published online Nov 26.
4. Centers for Disease Control and Prevention 2014 Ebola outbreak in West Africa - case counts http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html 2015 (accessed Feb 23, 2015).
5. X Qiu, G Wong, L Fernando et al. mAbs and Ad-vectored IFN-alpha therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms Sci Transl Med 5 2013 207ra143
6. M Balter Emerging diseases. On the trail of Ebola and Marburg viruses Science 290 2000 923 925
7. H Feldmann, HD Klenk Marburg and Ebola viruses Adv Virus Res 47 1996 1 52
8. S Baize, D Pannetier, L Oestereich et al. Emergence of Zaire Ebola virus disease in Guinea N Engl J Med 371 2014 1418 1425
9. H Kibuuka, NM Berkowitz, M Millard et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial Lancet 2014 published online Dec 22. http://dx.doi.org/10.1016/S0140-6736(14)62385-0
10. T Rampling, K Ewer, G Bowyer et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report N Engl J Med 2015 10.1056/NEJMoa1411627 published online Jan 28.
11. JE Ledgerwood, P Costner, N Desai et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults Vaccine 29 2010 304 313
12. China Food and Drug Administration The standard guidelines for adverse reactions grading of vaccine clinical trials http://www.sda.gov.cn/WS01/CL1036/9350-5.html (accessed Sept 6, 2014).
13. MC Sprangers, W Lakhai, W Koudstaal et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors J Clin Microbiol 41 2003 5046 5052
14. M Bull, D Lee, J Stucky et al. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials J Immunol Methods 322 2007 57 69
15. H Horton, EP Thomas, JA Stucky et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination J Immunol Methods 323 2007 39 54
16. SP Schoenberger CD69 guides CD4+ T cells to the seat of memory Proc Natl Acad Sci USA 109 2012 8358 8359
17. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. 2014; Nat Med 20: 1126-29.
18. BS Malaeb, TA Gardner, V Margulis et al. Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants Urology 66 2005 830 834
19. TW Geisbert, M Bailey, L Hensley et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge J Virol 85 2011 4222 4233
20. P Abbink, AA Lemckert, BA Ewald et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D J Virol 81 2007 4654 4663
21. E Nwanegbo, E Vardas, W Gao et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States Clin Diagn Lab Immunol 11 2004 351 357
22. NJ Sullivan, L Hensley, C Asiedu et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates Nat Med 17 2011 1128 1131
23. NJ Sullivan, TW Geisbert, JB Geisbert et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs PLoS Med 3 2006 e177
24. GE Gray, Z Moodie, B Metch et al. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study Lancet Infect Dis 14 2014 388 396
25. H Hu, MA Eller, S Zafar et al. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals Proc Natl Acad Sci USA 111 2014 13439 13444
26. G Gray, S Buchbinder, A Duerr Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine Curr Opin HIV AIDS 5 2010 357 361
27. GE Gray, M Allen, Z Moodie et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study Lancet Infect Dis 11 2011 507 515